The Global In Situ Hybridization Market size is expected to reach $1.8 billion by 2028, rising at a market growth of 6.9% CAGR during the forecast period.
In situ hybridization (ISH) is a kind of hybridization which locates a particular DNA or RNA sequence in a portion or section of tissue, or when the tissue is small sufficiently, in the whole tissue, in cells, or in circulating tumour cells. It uses a labeled complementary DNA, RNA, or modified nucleic acid strand. Immunohistochemistry, which often localizes proteins in tissue slices, differs from this.
Understanding genes' arrangement, control, and function requires knowing where particular nucleic acid sequences are located on chromosomes or in tissues, which is accomplished using in situ hybridization. Currently, the main methods in use include fluorescent in situ hybridization to identify chromosomal sequences, entire mount in situ hybridization, double identification of RNAs and RNA plus protein, and in situ hybridization to mRNA using oligonucleotide and RNA probes.
One method for figuring out the chromosomal structure is DNA ISH. For instance, fluorescent DNA ISH (FISH) may be employed in medical diagnostic procedures to evaluate chromosomal integrity. A unique nucleic acid sequence may be found and precisely localized inside a single cell using in situ hybridization. Through complementary base pairing, also known as hybridization, with a detectable nucleic acid segment known as a probe, the nucleic acid sequence is selectively bound in a tissue slice.
Three key benefits of in situ hybridization (ISH) are its high sensitivity, exact anatomical localization, and potential for measurement. The nucleic acid cannot be precisely localized inside a tissue using the blotting methods often employed for nucleic acid detection after homogenizing tissues, nucleic acid extraction, and hybridization. Additionally, the blotting techniques could be less sensitive: if just a small number of cells express an adequate quantity of nucleic acid, they would not be picked up by blotting after tissue homogenization but would be by ISH. Nevertheless, ISH is the go-to technique for detecting, localizing, and quantifying nucleic acids, particularly in diverse tissues like the brain.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
In situ hybridization (ISH) is a kind of hybridization which locates a particular DNA or RNA sequence in a portion or section of tissue, or when the tissue is small sufficiently, in the whole tissue, in cells, or in circulating tumour cells. It uses a labeled complementary DNA, RNA, or modified nucleic acid strand. Immunohistochemistry, which often localizes proteins in tissue slices, differs from this.
Understanding genes' arrangement, control, and function requires knowing where particular nucleic acid sequences are located on chromosomes or in tissues, which is accomplished using in situ hybridization. Currently, the main methods in use include fluorescent in situ hybridization to identify chromosomal sequences, entire mount in situ hybridization, double identification of RNAs and RNA plus protein, and in situ hybridization to mRNA using oligonucleotide and RNA probes.
One method for figuring out the chromosomal structure is DNA ISH. For instance, fluorescent DNA ISH (FISH) may be employed in medical diagnostic procedures to evaluate chromosomal integrity. A unique nucleic acid sequence may be found and precisely localized inside a single cell using in situ hybridization. Through complementary base pairing, also known as hybridization, with a detectable nucleic acid segment known as a probe, the nucleic acid sequence is selectively bound in a tissue slice.
Three key benefits of in situ hybridization (ISH) are its high sensitivity, exact anatomical localization, and potential for measurement. The nucleic acid cannot be precisely localized inside a tissue using the blotting methods often employed for nucleic acid detection after homogenizing tissues, nucleic acid extraction, and hybridization. Additionally, the blotting techniques could be less sensitive: if just a small number of cells express an adequate quantity of nucleic acid, they would not be picked up by blotting after tissue homogenization but would be by ISH. Nevertheless, ISH is the go-to technique for detecting, localizing, and quantifying nucleic acids, particularly in diverse tissues like the brain.
COVID-19 Impact Analysis
The COVID-19 pandemic is anticipated to have a significant impact on the market. With the introduction of the SARS-CoV-2 virus, already elevated lab testing requirements became even more global to keep up with enhanced testing criteria to identify probable instances of COVID-19. Thus, there is a considerable increase in the need for clinical diagnostics. The new coronavirus pandemic has created significant disruptions in the healthcare industries all around the globe. A considerable fall in precancer and cancer diagnoses was seen at the pandemic's height because fewer screening tests were conducted. These variables could have recently made in-situ hybridization less effective as a molecular diagnostic tool for cancer. However, the tremendous advancement of FISH probes to detect SARS-CoV-2 RNA in infected cells may have a favorable impact on the sector in the future.Market Growth Factors
Increasing cancer incidence
Numerous research on human illnesses conducted over the last several decades has shown recurring genetic aberrations as probable initiating factors for several malignancies. The prevalence of cancer has increased on a global scale. In 2020, cancer will account for over 10 million fatalities, or approximately one in every six fatalities, making it the leading cause of death worldwide. The most common forms of cancer include breast, colon, lung, rectum, and prostate. About one-third of cancer-related deaths are caused by smoking, having a high body mass index, consuming alcohol, consuming less fruits and vegetables, and not exercising.Rising healthcare costs
The increasing quantity and magnitude of investments made in the healthcare industry by governments of different nations are one of the primary drivers of the market's growth. Because of their rapid economic growth and rising healthcare expenses, it is projected that more emerging countries will have more access to high-quality healthcare. This is seen as a sign that the market for in situ hybridization is growing favorably. Due to the increase in health conditions, these countries now have a greater need than ever for different treatments and equipment. Therefore, each of these countries' governments emphasizes increasing the number of payment choices and enhancing citizen access to high-quality healthcare services. During the anticipated period, the market expansion is also fueled by the rising investment in the healthcare sectors.Market Restraining Factors
Lack of skilled workers
Many emerging and underdeveloped countries currently have a shortage of qualified professionals who can properly provide therapies. The prevalence of this problem is substantially higher in less developed countries and regions. These nations are anticipated to have a low supply of skilled surgeons and a sizable target patient population base. The molecular details of a chromosome or gene must be understood to perform an ISH-based test. Another obstacle to the industry's expansion is the resistance to switching from manual to automated processes. Thus, the widespread adoption of ISH-based diagnosis is constrained, especially in developing nations, by the need for more competent, trained, and technically aware laboratory staff.Technology Outlook
Based on technology, the in situ hybridization market is divided into Chromogenic In Situ Hybridization (CISH) and Fluorescent In Situ Hybridization (FISH). The Fluorescence In-Situ Hybridization (FISH) segment led the in situ hybridization market in 2021. Using complementary fluorescent probes which attach to the chromosomes at certain places, FISH is a kind of ISH. It gives researchers a way to map and see the genetic components of a single cell. This market category dominated the technology-based market in 2022 because of the broad range of applications it offers. For example, in cytogenetics, this method is used to comprehend diverse chromosomal abnormalities and genetic alterations.Probe Outlook
Based on the Probe, the in situ hybridization market is divided into the DNA and RNA. The DNA segment accounted for the largest revenue share in the market in 2021. In ISH, a probe made of tagged complementary single-stranded DNA binds to a particular sequence on the target DNA. The quickness with which tests may be run is one of the significant advantages of DNA probes, making this method one of the critical cytogenetic diagnostic techniques. One of the main factors driving the use of DNA probes for therapeutic use is breast cancer.Product Outlook
Based on product, the in situ hybridization market is segmented into instruments, kits & probes, software, and services. The kits and probes market segment accounted for a considerable revenue share in the in situ hybridization industry in 2021. The need for these goods is anticipated to increase as target conditions like cancer become more prevalent. In addition, the prevalence of genetic disorders such as leukaemia, solid tumors, lymphoma, and autism is expected to rise, accelerating the use of the FISH and CISH probe.Application Outlook
Based on application, the in situ hybridization market is divided into cancer, cytogenetics, developmental biology, infectious diseases, and others. The infectious illnesses segment is anticipated to grow at high rate during the forecast period. FISH (Fluorescent In Situ Hybridization), a technique used in infectiology to detect contagious microorganisms, integrates laboratory medicine with molecular genetics technology. While maintaining cell integrity, fluorescence in situ hybridization (FISH) is used to locate and identify nucleotide sequences in various materials.End-Use Outlook
Based on end-use, the in situ hybridization market is segmented into research and diagnostic labs, CROs, academic institutions, and others. The contract research organizations (CROs) showcased the prominent revenue share in the market in 2021. Many organizations contract out their research and clinical trials to CROs, and reasons including a specialized staff, lower costs for businesses, and increased efficiency might motivate enterprises and other organizations to do the same. Therefore, the profitable expansion of this market throughout the anticipated time may be attributable to all of the aforementioned elements.Regional Outlook
Based on region, the in situ hybridization market is classified into North America, Europe, Asia Pacific, and LAMEA. The North American region registered the largest revenue share in the market in 2021. This is explained by the widespread use of ISH in R&D in this area. The rising use of ISH, which allows early illness detection, is also a result of the availability of technologically advanced infrastructure. In Situ Hybridization (ISH) market expansion in this area is also anticipated to be fueled by significant companies in the sector and the introduction of cutting-edge products.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Abbott Laboratories, PerkinElmer, Inc., Agilent Technologies, Inc., Merck Group, Bio-Rad Laboratories, Inc., Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.), Danaher Corporation (Leica Biosystems), F. Hoffmann-La Roche Ltd., and Neogenomics, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Technology
- Fluorescent In Situ Hybridization (FISH)
- Chromogenic In Situ Hybridization (CISH)
By End Use
- Research & Diagnostic Laboratories
- Academic Institutes
- CROs
- Others
By Application
- Cancer
- Cytogenetics
- Developmental Biology
- Infectious Diseases
- Others
By Product
- Instruments
- Kits & Probes
- Software
- Services
By Probe
- DNA
- RNA
By Geography
North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc
- Abbott Laboratories
- PerkinElmer, Inc
- Agilent Technologies, Inc
- Merck Group
- Bio-Rad Laboratories, Inc
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd
- Neogenomics, Inc
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global In Situ Hybridization Market, by Technology
1.4.2 Global In Situ Hybridization Market, by End Use
1.4.3 Global In Situ Hybridization Market, by Application
1.4.4 Global In Situ Hybridization Market, by Product
1.4.5 Global In Situ Hybridization Market, by Probe
1.4.6 Global In Situ Hybridization Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global In Situ Hybridization Market by Technology
3.1 Global Fluorescent In Situ Hybridization (FISH) Market by Region
3.2 Global Chromogenic In Situ Hybridization (CISH) Market by Region
Chapter 4. Global In Situ Hybridization Market by End-use
4.1 Global Research & Diagnostic Laboratories Market by Region
4.2 Global Academic Institutes Market by Region
4.3 Global CROs Market by Region
4.4 Global Others Market by Region
Chapter 5. Global In Situ Hybridization Market by Application
5.1 Global Cancer Market by Region
5.2 Global Cytogenetics Market by Region
5.3 Global Developmental Biology Market by Region
5.4 Global Infectious Diseases Market by Region
5.5 Global Others Market by Region
Chapter 6. Global In Situ Hybridization Market by Product
6.1 Global Instruments Market by Region
6.2 Global Kits & Probes Market by Region
6.3 Global Software Market by Region
6.4 Global Services Market by Region
Chapter 7. Global In Situ Hybridization Market by Probe
7.1 Global DNA Market by Region
7.2 Global RNA Market by Region
Chapter 8. Global In Situ Hybridization Market by Region
8.1 North America In Situ Hybridization Market
8.1.1 North America In Situ Hybridization Market by Technology
8.1.1.1 North America Fluorescent In Situ Hybridization (FISH) Market by Country
8.1.1.2 North America Chromogenic In Situ Hybridization (CISH) Market by Country
8.1.2 North America In Situ Hybridization Market by End-use
8.1.2.1 North America Research & Diagnostic Laboratories Market by Country
8.1.2.2 North America Academic Institutes Market by Country
8.1.2.3 North America CROs Market by Country
8.1.2.4 North America Others Market by Country
8.1.3 North America In Situ Hybridization Market by Application
8.1.3.1 North America Cancer Market by Country
8.1.3.2 North America Cytogenetics Market by Country
8.1.3.3 North America Developmental Biology Market by Country
8.1.3.4 North America Infectious Diseases Market by Country
8.1.3.5 North America Others Market by Country
8.1.4 North America In Situ Hybridization Market by Product
8.1.4.1 North America Instruments Market by Country
8.1.4.2 North America Kits & Probes Market by Country
8.1.4.3 North America Software Market by Country
8.1.4.4 North America Services Market by Country
8.1.5 North America In Situ Hybridization Market by Probe
8.1.5.1 North America DNA Market by Country
8.1.5.2 North America RNA Market by Country
8.1.6 North America In Situ Hybridization Market by Country
8.1.6.1 US In Situ Hybridization Market
8.1.6.1.1 US In Situ Hybridization Market by Technology
8.1.6.1.2 US In Situ Hybridization Market by End-use
8.1.6.1.3 US In Situ Hybridization Market by Application
8.1.6.1.4 US In Situ Hybridization Market by Product
8.1.6.1.5 US In Situ Hybridization Market by Probe
8.1.6.2 Canada In Situ Hybridization Market
8.1.6.2.1 Canada In Situ Hybridization Market by Technology
8.1.6.2.2 Canada In Situ Hybridization Market by End-use
8.1.6.2.3 Canada In Situ Hybridization Market by Application
8.1.6.2.4 Canada In Situ Hybridization Market by Product
8.1.6.2.5 Canada In Situ Hybridization Market by Probe
8.1.6.3 Mexico In Situ Hybridization Market
8.1.6.3.1 Mexico In Situ Hybridization Market by Technology
8.1.6.3.2 Mexico In Situ Hybridization Market by End-use
8.1.6.3.3 Mexico In Situ Hybridization Market by Application
8.1.6.3.4 Mexico In Situ Hybridization Market by Product
8.1.6.3.5 Mexico In Situ Hybridization Market by Probe
8.1.6.4 Rest of North America In Situ Hybridization Market
8.1.6.4.1 Rest of North America In Situ Hybridization Market by Technology
8.1.6.4.2 Rest of North America In Situ Hybridization Market by End-use
8.1.6.4.3 Rest of North America In Situ Hybridization Market by Application
8.1.6.4.4 Rest of North America In Situ Hybridization Market by Product
8.1.6.4.5 Rest of North America In Situ Hybridization Market by Probe
8.2 Europe In Situ Hybridization Market
8.2.1 Europe In Situ Hybridization Market by Technology
8.2.1.1 Europe Fluorescent In Situ Hybridization (FISH) Market by Country
8.2.1.2 Europe Chromogenic In Situ Hybridization (CISH) Market by Country
8.2.2 Europe In Situ Hybridization Market by End-use
8.2.2.1 Europe Research & Diagnostic Laboratories Market by Country
8.2.2.2 Europe Academic Institutes Market by Country
8.2.2.3 Europe CROs Market by Country
8.2.2.4 Europe Others Market by Country
8.2.3 Europe In Situ Hybridization Market by Application
8.2.3.1 Europe Cancer Market by Country
8.2.3.2 Europe Cytogenetics Market by Country
8.2.3.3 Europe Developmental Biology Market by Country
8.2.3.4 Europe Infectious Diseases Market by Country
8.2.3.5 Europe Others Market by Country
8.2.4 Europe In Situ Hybridization Market by Product
8.2.4.1 Europe Instruments Market by Country
8.2.4.2 Europe Kits & Probes Market by Country
8.2.4.3 Europe Software Market by Country
8.2.4.4 Europe Services Market by Country
8.2.5 Europe In Situ Hybridization Market by Probe
8.2.5.1 Europe DNA Market by Country
8.2.5.2 Europe RNA Market by Country
8.2.6 Europe In Situ Hybridization Market by Country
8.2.6.1 Germany In Situ Hybridization Market
8.2.6.1.1 Germany In Situ Hybridization Market by Technology
8.2.6.1.2 Germany In Situ Hybridization Market by End-use
8.2.6.1.3 Germany In Situ Hybridization Market by Application
8.2.6.1.4 Germany In Situ Hybridization Market by Product
8.2.6.1.5 Germany In Situ Hybridization Market by Probe
8.2.6.2 UK In Situ Hybridization Market
8.2.6.2.1 UK In Situ Hybridization Market by Technology
8.2.6.2.2 UK In Situ Hybridization Market by End-use
8.2.6.2.3 UK In Situ Hybridization Market by Application
8.2.6.2.4 UK In Situ Hybridization Market by Product
8.2.6.2.5 UK In Situ Hybridization Market by Probe
8.2.6.3 France In Situ Hybridization Market
8.2.6.3.1 France In Situ Hybridization Market by Technology
8.2.6.3.2 France In Situ Hybridization Market by End-use
8.2.6.3.3 France In Situ Hybridization Market by Application
8.2.6.3.4 France In Situ Hybridization Market by Product
8.2.6.3.5 France In Situ Hybridization Market by Probe
8.2.6.4 Russia In Situ Hybridization Market
8.2.6.4.1 Russia In Situ Hybridization Market by Technology
8.2.6.4.2 Russia In Situ Hybridization Market by End-use
8.2.6.4.3 Russia In Situ Hybridization Market by Application
8.2.6.4.4 Russia In Situ Hybridization Market by Product
8.2.6.4.5 Russia In Situ Hybridization Market by Probe
8.2.6.5 Spain In Situ Hybridization Market
8.2.6.5.1 Spain In Situ Hybridization Market by Technology
8.2.6.5.2 Spain In Situ Hybridization Market by End-use
8.2.6.5.3 Spain In Situ Hybridization Market by Application
8.2.6.5.4 Spain In Situ Hybridization Market by Product
8.2.6.5.5 Spain In Situ Hybridization Market by Probe
8.2.6.6 Italy In Situ Hybridization Market
8.2.6.6.1 Italy In Situ Hybridization Market by Technology
8.2.6.6.2 Italy In Situ Hybridization Market by End-use
8.2.6.6.3 Italy In Situ Hybridization Market by Application
8.2.6.6.4 Italy In Situ Hybridization Market by Product
8.2.6.6.5 Italy In Situ Hybridization Market by Probe
8.2.6.7 Rest of Europe In Situ Hybridization Market
8.2.6.7.1 Rest of Europe In Situ Hybridization Market by Technology
8.2.6.7.2 Rest of Europe In Situ Hybridization Market by End-use
8.2.6.7.3 Rest of Europe In Situ Hybridization Market by Application
8.2.6.7.4 Rest of Europe In Situ Hybridization Market by Product
8.2.6.7.5 Rest of Europe In Situ Hybridization Market by Probe
8.3 Asia Pacific In Situ Hybridization Market
8.3.1 Asia Pacific In Situ Hybridization Market by Technology
8.3.1.1 Asia Pacific Fluorescent In Situ Hybridization (FISH) Market by Country
8.3.1.2 Asia Pacific Chromogenic In Situ Hybridization (CISH) Market by Country
8.3.2 Asia Pacific In Situ Hybridization Market by End-use
8.3.2.1 Asia Pacific Research & Diagnostic Laboratories Market by Country
8.3.2.2 Asia Pacific Academic Institutes Market by Country
8.3.2.3 Asia Pacific CROs Market by Country
8.3.2.4 Asia Pacific Others Market by Country
8.3.3 Asia Pacific In Situ Hybridization Market by Application
8.3.3.1 Asia Pacific Cancer Market by Country
8.3.3.2 Asia Pacific Cytogenetics Market by Country
8.3.3.3 Asia Pacific Developmental Biology Market by Country
8.3.3.4 Asia Pacific Infectious Diseases Market by Country
8.3.3.5 Asia Pacific Others Market by Country
8.3.4 Asia Pacific In Situ Hybridization Market by Product
8.3.4.1 Asia Pacific Instruments Market by Country
8.3.4.2 Asia Pacific Kits & Probes Market by Country
8.3.4.3 Asia Pacific Software Market by Country
8.3.4.4 Asia Pacific Services Market by Country
8.3.5 Asia Pacific In Situ Hybridization Market by Probe
8.3.5.1 Asia Pacific DNA Market by Country
8.3.5.2 Asia Pacific RNA Market by Country
8.3.6 Asia Pacific In Situ Hybridization Market by Country
8.3.6.1 China In Situ Hybridization Market
8.3.6.1.1 China In Situ Hybridization Market by Technology
8.3.6.1.2 China In Situ Hybridization Market by End-use
8.3.6.1.3 China In Situ Hybridization Market by Application
8.3.6.1.4 China In Situ Hybridization Market by Product
8.3.6.1.5 China In Situ Hybridization Market by Probe
8.3.6.2 Japan In Situ Hybridization Market
8.3.6.2.1 Japan In Situ Hybridization Market by Technology
8.3.6.2.2 Japan In Situ Hybridization Market by End-use
8.3.6.2.3 Japan In Situ Hybridization Market by Application
8.3.6.2.4 Japan In Situ Hybridization Market by Product
8.3.6.2.5 Japan In Situ Hybridization Market by Probe
8.3.6.3 India In Situ Hybridization Market
8.3.6.3.1 India In Situ Hybridization Market by Technology
8.3.6.3.2 India In Situ Hybridization Market by End-use
8.3.6.3.3 India In Situ Hybridization Market by Application
8.3.6.3.4 India In Situ Hybridization Market by Product
8.3.6.3.5 India In Situ Hybridization Market by Probe
8.3.6.4 South Korea In Situ Hybridization Market
8.3.6.4.1 South Korea In Situ Hybridization Market by Technology
8.3.6.4.2 South Korea In Situ Hybridization Market by End-use
8.3.6.4.3 South Korea In Situ Hybridization Market by Application
8.3.6.4.4 South Korea In Situ Hybridization Market by Product
8.3.6.4.5 South Korea In Situ Hybridization Market by Probe
8.3.6.5 Singapore In Situ Hybridization Market
8.3.6.5.1 Singapore In Situ Hybridization Market by Technology
8.3.6.5.2 Singapore In Situ Hybridization Market by End-use
8.3.6.5.3 Singapore In Situ Hybridization Market by Application
8.3.6.5.4 Singapore In Situ Hybridization Market by Product
8.3.6.5.5 Singapore In Situ Hybridization Market by Probe
8.3.6.6 Malaysia In Situ Hybridization Market
8.3.6.6.1 Malaysia In Situ Hybridization Market by Technology
8.3.6.6.2 Malaysia In Situ Hybridization Market by End-use
8.3.6.6.3 Malaysia In Situ Hybridization Market by Application
8.3.6.6.4 Malaysia In Situ Hybridization Market by Product
8.3.6.6.5 Malaysia In Situ Hybridization Market by Probe
8.3.6.7 Rest of Asia Pacific In Situ Hybridization Market
8.3.6.7.1 Rest of Asia Pacific In Situ Hybridization Market by Technology
8.3.6.7.2 Rest of Asia Pacific In Situ Hybridization Market by End-use
8.3.6.7.3 Rest of Asia Pacific In Situ Hybridization Market by Application
8.3.6.7.4 Rest of Asia Pacific In Situ Hybridization Market by Product
8.3.6.7.5 Rest of Asia Pacific In Situ Hybridization Market by Probe
8.4 LAMEA In Situ Hybridization Market
8.4.1 LAMEA In Situ Hybridization Market by Technology
8.4.1.1 LAMEA Fluorescent In Situ Hybridization (FISH) Market by Country
8.4.1.2 LAMEA Chromogenic In Situ Hybridization (CISH) Market by Country
8.4.2 LAMEA In Situ Hybridization Market by End-use
8.4.2.1 LAMEA Research & Diagnostic Laboratories Market by Country
8.4.2.2 LAMEA Academic Institutes Market by Country
8.4.2.3 LAMEA CROs Market by Country
8.4.2.4 LAMEA Others Market by Country
8.4.3 LAMEA In Situ Hybridization Market by Application
8.4.3.1 LAMEA Cancer Market by Country
8.4.3.2 LAMEA Cytogenetics Market by Country
8.4.3.3 LAMEA Developmental Biology Market by Country
8.4.3.4 LAMEA Infectious Diseases Market by Country
8.4.3.5 LAMEA Others Market by Country
8.4.4 LAMEA In Situ Hybridization Market by Product
8.4.4.1 LAMEA Instruments Market by Country
8.4.4.2 LAMEA Kits & Probes Market by Country
8.4.4.3 LAMEA Software Market by Country
8.4.4.4 LAMEA Services Market by Country
8.4.5 LAMEA In Situ Hybridization Market by Probe
8.4.5.1 LAMEA DNA Market by Country
8.4.5.2 LAMEA RNA Market by Country
8.4.6 LAMEA In Situ Hybridization Market by Country
8.4.6.1 Brazil In Situ Hybridization Market
8.4.6.1.1 Brazil In Situ Hybridization Market by Technology
8.4.6.1.2 Brazil In Situ Hybridization Market by End-use
8.4.6.1.3 Brazil In Situ Hybridization Market by Application
8.4.6.1.4 Brazil In Situ Hybridization Market by Product
8.4.6.1.5 Brazil In Situ Hybridization Market by Probe
8.4.6.2 Argentina In Situ Hybridization Market
8.4.6.2.1 Argentina In Situ Hybridization Market by Technology
8.4.6.2.2 Argentina In Situ Hybridization Market by End-use
8.4.6.2.3 Argentina In Situ Hybridization Market by Application
8.4.6.2.4 Argentina In Situ Hybridization Market by Product
8.4.6.2.5 Argentina In Situ Hybridization Market by Probe
8.4.6.3 UAE In Situ Hybridization Market
8.4.6.3.1 UAE In Situ Hybridization Market by Technology
8.4.6.3.2 UAE In Situ Hybridization Market by End-use
8.4.6.3.3 UAE In Situ Hybridization Market by Application
8.4.6.3.4 UAE In Situ Hybridization Market by Product
8.4.6.3.5 UAE In Situ Hybridization Market by Probe
8.4.6.4 Saudi Arabia In Situ Hybridization Market
8.4.6.4.1 Saudi Arabia In Situ Hybridization Market by Technology
8.4.6.4.2 Saudi Arabia In Situ Hybridization Market by End-use
8.4.6.4.3 Saudi Arabia In Situ Hybridization Market by Application
8.4.6.4.4 Saudi Arabia In Situ Hybridization Market by Product
8.4.6.4.5 Saudi Arabia In Situ Hybridization Market by Probe
8.4.6.5 South Africa In Situ Hybridization Market
8.4.6.5.1 South Africa In Situ Hybridization Market by Technology
8.4.6.5.2 South Africa In Situ Hybridization Market by End-use
8.4.6.5.3 South Africa In Situ Hybridization Market by Application
8.4.6.5.4 South Africa In Situ Hybridization Market by Product
8.4.6.5.5 South Africa In Situ Hybridization Market by Probe
8.4.6.6 Nigeria In Situ Hybridization Market
8.4.6.6.1 Nigeria In Situ Hybridization Market by Technology
8.4.6.6.2 Nigeria In Situ Hybridization Market by End-use
8.4.6.6.3 Nigeria In Situ Hybridization Market by Application
8.4.6.6.4 Nigeria In Situ Hybridization Market by Product
8.4.6.6.5 Nigeria In Situ Hybridization Market by Probe
8.4.6.7 Rest of LAMEA In Situ Hybridization Market
8.4.6.7.1 Rest of LAMEA In Situ Hybridization Market by Technology
8.4.6.7.2 Rest of LAMEA In Situ Hybridization Market by End-use
8.4.6.7.3 Rest of LAMEA In Situ Hybridization Market by Application
8.4.6.7.4 Rest of LAMEA In Situ Hybridization Market by Product
8.4.6.7.5 Rest of LAMEA In Situ Hybridization Market by Probe
Chapter 9. Company Profiles
9.1 Thermo Fisher Scientific, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Segmental and Regional Analysis
9.1.4 Research & Development Expense
9.2 Abbott Laboratories
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 PerkinElmer, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Agilent Technologies, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Partnerships, Collaborations, and Agreements:
9.6 Bio-Rad laboratories, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Segmental and Regional Analysis
9.6.4 Research & Development Expenses
9.7 Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expenses
9.8 Danaher Corporation (Leica Biosystems)
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.9 F. Hoffmann-La Roche Ltd.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Segmental and Regional Analysis
9.9.4 Research & Development Expense
9.10. Neogenomics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental Analysis
9.10.4 Research & Development Expenses
Companies Mentioned
- Thermo Fisher Scientific, Inc.
- Abbott Laboratories
- PerkinElmer, Inc.
- Agilent Technologies, Inc.
- Merck Group
- Bio-Rad Laboratories, Inc.
- Bio-Techne Corporation (Advanced Cell Diagnostics, Inc.)
- Danaher Corporation (Leica Biosystems)
- F. Hoffmann-La Roche Ltd.
- Neogenomics, Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 306 |
| Published | January 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1143.2 Million |
| Forecasted Market Value ( USD | $ 1808.8 Million |
| Compound Annual Growth Rate | 6.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
